Although China represents a short-term headwind around both box office trends and system installation timing, Imax's underlying demand trends and the long-term installation outlook remain solid, B. Riley FBR analyst Eric Wold tells investors in a post-earnings research note. While lowered his 2020 and 2021 estimates given the China uncertainty, the analyst believes the recent stock weakness is discounting "non-existent long-term issues coming out of the China situation." As such, Wold would not be surprised if management is taking advantage of the recent weakness with accelerated share repurchases. He reiterates a Buy rating on Imax with a $26 price target.